Concepedia

Desmond Chee

DC

Statistics

Publications

14

Citations

907

H-Index

13

Active since

2010

Affiliations

Royal Devon & Exeter NHS Foundation Trust(Current)

University of Exeter

Western General Hospital

University of Hull

King's College London

Desmond Chee is an author at Royal Devon & Exeter NHS Foundation Trust specializing in immunotherapy, immunogenicity of biologic agents, and immunology.

ORCID

Publications per year

2010–2022

14

Publications

14

Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD

Nicholas A. Kennedy, Simeng Lin, James Goodhand et al. · Gut · 2021 · 280 citations · Full text

, , +17

Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab.

Nicholas A. Kennedy, James Goodhand, Claire Bewshea et al. · Edinburgh Research Explorer (University of Edinburgh) · 2021 · 163 citations · Full text

, , +17

Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience

Sailish Honap, Desmond Chee, Thomas Chapman et al. · Journal of Crohn s and Colitis · 2020 · 123 citations

, , +17

Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab

Simeng Lin, Nicholas A. Kennedy, Aamir Saifuddin et al. · Nature Communications · 2022 · 81 citations · Full text

, , +17

Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients

Neil Chanchlani, Simeng Lin, Desmond Chee et al. · Journal of Crohn s and Colitis · 2021 · 47 citations · Full text

, , +17

1–5 of 14